SEC 13F Intelligence

Managers / Q4 2021 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$1.3B
Q4 2021
Positions
43
Filings on Record
16
2019–present window
Filed
Feb 8, 2022
original filing

Summary

Frazier Management LLC reported $1.3B in U.S.-listed holdings across 43 positions for Q4 2021.

Its largest position, ARQT, represents 13.5% of the portfolio.

Compared with Q3 2021, the fund opened 6 new positions and exited 4.

Portfolio Metrics

Turnover
+20.0%
vs prior filed quarter
Top-10 Concentration
+55.9%
share of reported value
Largest Position
+13.5%
Arcutis Biotherapeutics
New / Exited
6 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 74.5%Other: 19.8%ADR: 5.7%
  • Common Stock · 74.5% · $967M
  • Other · 19.8% · $257M
  • ADR · 5.7% · $74M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PARDES BIOSCIENCES INCNEW+2.46M2.46M+$40M$40M
SLNSILENCE THERAPEUTICS PLCNEW+886.2K886.2K+$21M$21M
MERUS N VNEW+559.2K559.2K+$18M$18M
TRICIDA INCNEW+1.78M1.78M+$17M$17M
COGTCOGENT BIOSCIENCES INCNEW+1.77M1.77M+$15M$15M
ARVNARVINAS INCNEW+163.8K163.8K+$13M$13M
KALVISTA PHARMACEUTICALS INCADDED+1.15M1.31M+$15M$17M
SNDXSYNDAX PHARMACEUTICALS INCADDED+1.58M2.77M+$38M$61M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

43 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM13.47%$175M8.43M
2PHATPHATHOM PHARMACEUTICALS INChistory →COM8.82%$115M5.83M
3IMAGO BIOSCIENCES INCCOM5.42%$70M2.97M
4SNDXSYNDAX PHARMACEUTICALS INChistory →COM4.67%$61M2.77M
5GRITSTONE BIO INCCOM4.62%$60M4.67M
6MIRMMIRUM PHARMACEUTICALS INChistory →COM4.38%$57M3.57M
7PCVXVAXCYTE INChistory →COM4.23%$55M2.31M
8KRYSKRYSTAL BIOTECH INChistory →COM4.15%$54M771.3K
9PARDES BIOSCIENCES INCCOM3.10%$40M2.46M
10CRNXCRINETICS PHARMACEUTICALS INhistory →COM3.03%$39M1.38M
11CHINOOK THERAPEUTICS INCCOM2.98%$39M2.37M
12BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS2.60%$34M555.2K
13IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM2.57%$33M1.75M
14TARSTARSUS PHARMACEUTICALS INChistory →COM2.45%$32M1.42M
15PASSAGE BIO INCCOM2.45%$32M5.01M
16ANABANAPTYSBIO INChistory →COM2.41%$31M899.7K
17IVERIC BIO INCCOM2.37%$31M1.84M
18VRDNVIRIDIAN THERAPEUTICS INChistory →COM2.29%$30M1.51M
19SIERRA ONCOLOGY INCCOM NEW2.12%$27M1.26M
20SUTRO BIOPHARMA INCCOM2.04%$26M1.78M
21ALPINE IMMUNE SCIENCES INCCOM1.90%$25M1.78M
22SLNSILENCE THERAPEUTICS PLChistory →ADS1.63%$21M886.2K
23AUTLAUTOLUS THERAPEUTICS PLChistory →SPON ADS1.50%$19M3.75M
24MERUS N VCOM1.37%$18M559.2K
25REPLREPLIMUNE GROUP INChistory →COM1.36%$18M650.9K
26TYRATYRA BIOSCIENCES INChistory →COM1.35%$18M1.25M
27KALVISTA PHARMACEUTICALS INCCOM1.33%$17M1.31M
28TRICIDA INCCOM1.31%$17M1.78M
29COGTCOGENT BIOSCIENCES INChistory →COM1.17%$15M1.77M
30FRAZIER LIFESCIENCES ACQU COUNIT 12/09/20251.15%$15M1.50M
31ARVNARVINAS INChistory →COM1.04%$13M163.8K
32GRACELL BIOTECHNOLOGIES INCSPONSORED ADS0.77%$10M1.65M
33ESSA PHARMA INCCOM NEW0.59%$8M543.5K
34RGNXREGENXBIO INCCOM0.59%$8M235.8K
35AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.59%$8M951.8K
36ACRSACLARIS THERAPEUTICS INCCOM0.46%$6M408.3K
37MOLECULAR TEMPLATES INCCOM0.41%$5M1.37M
38APTINYX INCCOM0.39%$5M1.88M
39IMVTIMMUNOVANT INCCOM0.38%$5M585.8K
40SRRKSCHOLAR ROCK HLDG CORPCOM0.30%$4M156.0K
41EPIZYME INCCOM0.14%$2M739.4K
42ALLENA PHARMACEUTICALSCOM0.08%$978,0001.65M
43NABRIVA THERAPEUTICS PLCSHS0.02%$255,000425.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.